GSK's Trelegy Ellipta meets key goal in late-stage asthma study

British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to its lung medicines division that has been hit by generic competition.